- Home
- HCWB vs GOVX Comparison
HCWB vs GOVX Comparison
Compare HCWB & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- GOVX
- Stock Information
- Founded
- HCWB 2018
- GOVX 2001
- Country
- HCWB United States
- GOVX United States
- Employees
- HCWB N/A
- GOVX N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- HCWB Health Care
- GOVX Health Care
- Exchange
- HCWB Nasdaq
- GOVX Nasdaq
- Market Cap
- HCWB 17.2M
- GOVX 19.5M
- IPO Year
- HCWB 2021
- GOVX N/A
- Fundamental
- Price
- HCWB $0.39
- GOVX $1.67
- Analyst Decision
- HCWB
- GOVX Strong Buy
- Analyst Count
- HCWB 0
- GOVX 5
- Target Price
- HCWB N/A
- GOVX $14.20
- AVG Volume (30 Days)
- HCWB 18.3M
- GOVX 569.4K
- Earning Date
- HCWB 03-31-2025
- GOVX 03-03-2025
- Dividend Yield
- HCWB N/A
- GOVX N/A
- EPS Growth
- HCWB N/A
- GOVX N/A
- EPS
- HCWB N/A
- GOVX N/A
- Revenue
- HCWB $3,495,990.00
- GOVX $3,090,161.00
- Revenue This Year
- HCWB $229.19
- GOVX N/A
- Revenue Next Year
- HCWB N/A
- GOVX $150.51
- P/E Ratio
- HCWB N/A
- GOVX N/A
- Revenue Growth
- HCWB 22.27
- GOVX N/A
- 52 Week Low
- HCWB $0.21
- GOVX $1.09
- 52 Week High
- HCWB $2.52
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- HCWB 48.72
- GOVX 37.32
- Support Level
- HCWB $0.38
- GOVX $1.50
- Resistance Level
- HCWB $0.42
- GOVX $1.79
- Average True Range (ATR)
- HCWB 0.09
- GOVX 0.13
- MACD
- HCWB -0.00
- GOVX 0.01
- Stochastic Oscillator
- HCWB 4.48
- GOVX 29.82
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.